In Vivo Rnai
In Vivo Rnai - Related Videos
09:51
RNAi in C. elegans
0 Views •
2023
RNA interference (RNAi) is a widely used technique in which double stranded RNA is exogenously introduced into an organism, causing knockdown of a target gene. In the nematode, C. elegans, RNAi is particularly easy and effective because it can be delivered simply by feeding the worms bacteria that express double stranded RNA (dsRNA) that is complementary to a gene of interest. First, this video will introduce the concept of RNA interference and explain how it causes targeted gene knockdown.
08:47
RNAi-mediated Gene Knockdown and In Vivo Diuresis Assay in Adult Female Aedes aegypti Mosquitoes
0 Views •
Cited by 19 •
2012
In this protocol we combine RNAi-mediated gene silencing with an in vivo diuresis assay to study the effects knockdown of genes of interest has on mosquito fluid excretion.
07:56
Bacterial Delivery of RNAi Effectors: Transkingdom RNAi
0 Views •
Cited by 18 •
2010
For development of RNA interference (RNAi)-based therapies, a novel strategy was developed, transkingdom RNAi (tkRNAi). This technology uses non-pathogenic bacteria to produce and deliver therapeutic short hairpin RNA (shRNA) into target cells. Here, tkRNAi was successfully applied for reversal of classical ABCB1-mediated multidrug resistance (MDR) of cancer cells.
10:30
The C. elegans Excretory Canal as a Model for Intracellular Lumen Morphogenesis and In Vivo Polarized Membrane Biogenesis in a Single Cell: labeling by GFP-fusions, RNAi Interaction Screen and Imaging
0 Views •
Cited by 6 •
2017
The C. elegans excretory canal is a unique single-cell model for the visual in vivo analysis of de novo polarized membrane biogenesis. This protocol describes a combination of standard genetic/RNAi and imaging approaches, adaptable for the identification and characterization of molecules directing unicellular tubulogenesis, and apical membrane and lumen biogenesis.
02:29
Culturing and Maintenance of RNAi-Expressing Bacteria
0 Views •
2025
Source: Anderson, Q. L., et al., A High-throughput, High-content, Liquid-based C. elegans Pathosystem. J. Vis. Exp. (2018)This video demonstrates the preparation of RNA interference (RNAi) bacteria carrying plasmids to inhibit target gene expression. It outlines RNAi bacterial selection, growth, and induction steps to produce dsRNA-expressing plates for downstream assays.
FAQs
After delivery, siRNA loads into the RNA-induced silencing complex, or RISC. The complex uses the siRNA sequence to recognize complementary messenger RNA and cleave it. This reduces the amount of messenger RNA available to direct production of its encoded protein, linking sequence recognition at the RNA level to a measurable reduction in protein production within cells.
Stability affects whether delivered siRNA remains available long enough to reach and enter target cells. Biodistribution describes where the material travels within the organism, which influences the tissues exposed to the silencing signal. These factors determine whether gene reduction occurs in the intended biological location and help explain why delivery performance is central to experimental outcomes.
The method reduces production of a selected protein by lowering its messenger RNA, allowing researchers to associate that reduction with a biological outcome. Interpretation must account for off-target effects, because unintended silencing could contribute to the observed result. Careful attention to sequence-specific action and delivery behavior therefore strengthens conclusions about the targeted gene's function.
Lipid nanoparticles, viral vectors, and other carriers can transport siRNAs into living organisms. Their importance extends beyond simple delivery: carrier properties influence stability, biodistribution, and the possibility of reaching particular tissues. Selecting among these systems is therefore part of designing an experiment that connects siRNA administration with silencing in the intended biological setting.
Researchers can examine whether reducing a selected gene's expression changes production of its encoded protein and alters a biological phenotype in the organism. Those observations support functional genomics by connecting genes with biological roles. The same approach can also contribute to disease modeling when gene silencing is used to investigate processes relevant to disease.
In vivo RNAi is relevant when reducing expression of a selected gene may help investigate or address a disease-related process. Delivery systems can be evaluated for their ability to reach appropriate tissues, while stability, biodistribution, and off-target effects remain important considerations. These studies provide a foundation for exploring gene-silencing therapies rather than treating delivery as an incidental step.